Member Info for daveycaferacer

Indeed wbcham, the fact that NASDAQ drives the overall price means the strengthening pound is going against us at the moment. It still puzzles me that we have the same mcap that we had in Oct 2017........

Why is the Accustem listing taking so long? Currently they have taken/removed a valuable asset from Tiziana Shareholders by way of a capital reduction approved by the court, but have not compensated Shareholders for their loss, by issuing them Accustem shares. I'll have to read the documents but I cannot envisage the court giving a Company an open ended timeline on closure as it would allow Companies to hive off assets at will.

actually 430p was first reached in October 2017, so despite all the huge progress (2 drugs approved in China, NDA's in the U.S. and China etc etc etc) the market is valuing the Company at the same level as it was almost 4 years ago. The Company continues to deliver and meet its targets yet the market doesn't seem to care. I can only assume and hope that an Asian listing will attract a more realistic valuation.

The average therapeutic takes 10 years to go from Phase 1 to NDA submission then another 1 - 2 years for approval

Only 10% of Phase 1 drugs make it through to approval

I'm looking forward to the 2020 results next week, but probably more importantly I'm hoping for a update on Elunate sales since the contract change and how Sulanda is starting to perform171717. I am also always hopeful we may get some form of news on a HK or Star Exchange listing because the current listings don't seem to give much value to future growth of the Company (unlike Beigene's valuation!).

What is the difficulty in listing Accustem? The court agreed the capital reduction and currently Shareholders have had an asset removed from the Company without due compensation.

Tiziana Life Sciences do have a legal obligation to Shareholders regarding Accustem. The court approved the demerger and capital reduction on the basis that the divested assets would be distributed equitably to Tiziana Shareholders. Currently Shareholders have not received the divested assets that are due to them in the time the Company committed to.

"TILS has just completed a small phase 1 trial, Months away from being of any interest to the media."

Do you mean mainstream media or Biopharma media?
Usually I would agree if this was an oncology or immunology play but the rules are different for Covid. Once the full dataset is out there will be a lot of interest in the Biopharma media and probably some in the mainstream media.

I think that strategy with regards to posting is an excellent one Jatw and one I will align with myself.

Vaccines are the answer but we will always need therapeutics too as Covid is not going away

Given the fact the UK is way ahead of any other developed country in the world when it comes to the vaccine rollout, and that includes being way ahead of the inept and frankly disorganised EU, I can't see "they have screwed up from start to finish". Do you have anything interesting to say about the Tiziana investment case or just use Bulletin Boards to slander the Govt who no doubt pays your Universal Credit?

I agree, and there seems little point in timing them for the UK market which seems to have no interest in the Company. I hope a HK or Star Market listing will be the catalyst to realise the true value of the Company.

The JPM Healthcare conference webinar has been added to the Company website

https://www.chi-med.com/wp-content/uploads/2021/01/JPM21_HCM.mp4

It is interesting that once the full dataset is available from the Brazil trial the Company is considering conducting the P2 trial in the United States - that should raise awareness significantly

here is the link for anyone who hasn't got it

https://www.youtube.com/watch?v=eHui5s82bU0&feature=youtu.be

The Company's CRO and the Company will be in dialogue with the FDA - that's how the trials work

"What if the FDA fast tracked this one, would that make the process even faster?"

Yes there is a Fast Track process specifically for Covid therapeutics and the FDA will be aware of the data as they had to approve the trial in the first place

as a Reddit User and a regular on w/streetbets I sincerely doubt that to be the case, it's probably just daytraders cashing in as usual

5% rise today so probably an RNS tomorrow, which seems to be a common theme ;o-)

to your point about Covid P2 & P3 I believe that's why they submitted the SEC shelf registration, so they can do fundraisings as and when they need them, but they have more than enough cash for an expanded Covid trial and other Foralumab and Milciclib trials so no need to raise cash for quite a while yet